Cannabis Law and Access in Cyprus

Cyprus sits at an interesting crossroads in European cannabis law

Forty-seven countries in the WHO European Region have now introduced some form of medical cannabis legislation. Cyprus joined that list in 2019, and has since moved faster than most people expect from a small island nation still navigating EU membership constraints and a complicated geopolitical situation in Nicosia. I've spent the past couple of months pulling together the primary legislative sources , partly because I kept seeing inaccurate summaries circulating, partly because, honestly, it's the kind of policy archaeology I find genuinely interesting. Like unfolding a vintage survey map of a coastline that's shifted slightly since it was drawn.

This article focuses on the legal and regulatory framework as it stands. It is not Australian law. Nothing here should be read as advice to obtain, import, or seek access to any cannabis product. If you're an Australian reader, our own TGA-administered access pathways , the Special Access Scheme and Authorised Prescriber programme , are the relevant reference points for domestic access.

The medical cannabis framework: Law 180(I)/2017 and its amendments

Cyprus legalised cannabis for medical and scientific purposes under Law 180(I)/2017, which amended the Narcotic Drugs and Psychotropic Substances Law. The legislation established a licensing framework administered by the Ministry of Health, permitting cultivation, production, and supply of cannabis-based medicinal products under tightly controlled conditions.

The 2019 regulatory expansion; driven partly by economic development strategy and partly by pressure from patient advocacy groups, introduced provisions for domestic cultivation by licensed operators and clarified the import and export rules for pharmaceutical-grade material. Cyprus is a signatory to the 1961 UN Single Convention on Narcotic Drugs, which constrains how far any EU member state can liberalise; the 2019 amendments were carefully constructed to sit within those obligations.

Patients accessing cannabis-based medicines in Cyprus require a prescription from a licensed physician. The product must be authorised, and the supply chain, cultivation, processing, distribution; must be licensed by the Pharmaceutical Services of the Ministry of Health. Unauthorised supply remains a criminal offence.

From a pharmacological framing, the products that move through this system are typically standardised to specific THC and CBD ratios, sometimes described as full-spectrum extracts, meaning the finished product retains a range of cannabinoids and plant compounds rather than being refined to a single molecule. The rationale for that, to the extent it's discussed in regulatory guidance, touches on what researchers refer to as the entourage effect, the idea that the full phytochemical profile may be relevant to how the product behaves biologically. Worth noting that this remains an active area of research rather than settled science.

Decriminalisation of personal use: what the 2022 reforms actually changed

The more headline-grabbing development came in October 2022, when the Cypriot parliament passed amendments decriminalising the possession of small quantities of cannabis for personal use. This is not legalisation. The distinction matters, and I'd push back on any summary that conflates the two.

Under the reforms, possession of up to six grams of cannabis or up to two cannabis plants is treated as an administrative rather than criminal matter, subject to a fine rather than prosecution. Repeat offences or quantities above that threshold revert to criminal proceedings. Sale, supply, and trafficking remain serious criminal offences carrying substantial penalties.

The six-gram threshold was chosen to align roughly with comparable European decriminalisation frameworks, Portugal's model (which covers a broader range of substances) and Malta's 2021 recreational legalisation were both referenced in parliamentary debate, though Cyprus explicitly stopped short of Malta's approach. There is no legal recreational market in Cyprus. There is no licensed dispensary system for non-medical use. The decriminalisation reform removes criminal sanction for small personal quantities; it does not create a legal supply pathway for recreational users.

Regulatory oversight and product standards

Licensed medical cannabis operations in Cyprus fall under the oversight of the Pharmaceutical Services directorate, which sits within the Ministry of Health. The licensing criteria include Good Manufacturing Practice standards; GMP compliance is a requirement for operators seeking to export to other EU markets, which has been part of the economic rationale for Cyprus positioning itself as a regional cultivation hub.

Products moving through the licensed medical supply chain are subject to testing and specification requirements covering cannabinoid content, microbiological contamination, pesticide residues, and heavy metals. The cannabinoid profile of a product, whether it is a broad-spectrum extract, an isolate, or a full-spectrum preparation, must be accurately characterised and labelled.

There is no equivalent of Australia's ARTG (Australian Register of Therapeutic Goods) in Cyprus specifically, but products must comply with EU pharmaceutical directives where applicable. The EU regulatory landscape for cannabis-based medicines remains fragmented; each member state retains significant authority over scheduling and market authorisation, and Cyprus is no exception.

Hemp, CBD, and the low-THC question

Hemp cultivation; defined under EU law as Cannabis sativa L. with THC content not exceeding 0.2 per cent in the dry plant, is permitted in Cyprus under EU agricultural regulations. This sits separately from the medical cannabis framework.

The legal status of CBD products in Cyprus follows the broader EU position post the 2020 European Court of Justice Kanavape ruling, which found that CBD derived from the whole hemp plant cannot be classified as a narcotic under EU law when it does not produce psychoactive effects. In practice, this has opened a market for CBD-containing products, though the regulatory treatment, whether as a food supplement, novel food, or medicinal product; depends on the claims made and the form of the product. A CBD extract marketed with health claims would likely attract pharmaceutical regulation; a hemp seed oil sold as a food supplement would not.

Cannabidiol, for those less familiar with the chemistry, is a non-intoxicating cannabinoid that interacts with the endocannabinoid system through mechanisms distinct from THC, which primarily binds to CB1 receptors. CBD's interactions are more diffuse, including activity at CB2 receptors and modulation of endogenous cannabinoids like anandamide. None of that is a therapeutic claim, it's a mechanistic description of receptor pharmacology.

How this compares to other EU member states

Cyprus is neither the most liberal nor the most restrictive EU jurisdiction on cannabis. Germany's 2024 partial legalisation of recreational cannabis for adults generated far more international coverage. Malta remains the only EU member state with a fully operational adult-use regulatory framework. The Netherlands has its long-running tolerance policy, which is technically distinct from legalisation. Cyprus fits somewhere in the middle: a functional medical programme, decriminalisation of small personal quantities, and no recreational market.

My honest read of the Cyprus framework is that the 2019–2022 reforms were as much economic strategy as social policy. The island has positioned its agricultural sector to serve European medical cannabis demand, and the licensing structure reflects that outward orientation. Whether the domestic patient access system has kept pace with those commercial ambitions is a separate, harder question, and one the available public data doesn't fully answer yet.

What Australian readers should take from this

Comparative legal literacy has genuine value. Understanding how other jurisdictions have structured their cannabis frameworks; what they've classified as prescription-only, what they've decriminalised, how they've handled the hemp-versus-cannabis boundary, informs how we read our own regulatory architecture here.

In Australia, cannabis-based medicines sit under the Poisons Standard as either Schedule 4 (prescription only) or Schedule 8 (controlled drug) depending on THC content, with access flowing through TGA-administered pathways. Recreational cannabis remains illegal federally and in most states and territories. The ACT's personal use decriminalisation, which I'm quite familiar with, living in Canberra; is the outlier domestically, and it operates in a structurally similar way to what Cyprus introduced in 2022: administrative rather than criminal treatment for small quantities, with no legal supply pathway attached.

None of what Cyprus has done translates directly into Australian law, and nothing in this article is a basis for action on either side of the Pacific. But the comparison is worth knowing.

Sources

• Cyprus Country Drug Report 2023, European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)
• Medical Cannabis Hub, Therapeutic Goods Administration (TGA)
• The International Drug Control Conventions; United Nations Office on Drugs and Crime (UNODC)
• Case C-663/18 Kanavape Judgment, Court of Justice of the European Union

, Marcus Hale, Regulatory researcher, TGA & access law